RxDoctor Payments Data

Michael Zammit, MD

Vascular Surgery · Twin Falls, IDNPI 1841251188

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 65 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 18 manufacturers, the largest accounting for just 21.0% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $902, 2.5 times the $355 reported in 2019.

$3,943in general payments, 2019–2025

Across 65 payments — averaging $60.65 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$829
  • Shockwave Medical, Inc$519
  • Stryker$480
  • Philips North America LLC$456
  • Inari Medical, Inc.$441
  • Endologix LLC$242
  • plus $977 from 12 others

What the payments were for

  • Food & beverage$3,943100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,943 in reported general payments places this provider in the 60th percentile of 28 vascular surgery providers in Idaho.

See all vascular surgery providers in Idaho

Medicare billing

Part B allowed, 2024
$98,803
Medicare patients
338
Services billed
759

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XareltoRivaroxaban14$11,922
EliquisApixaban16$10,274
ClopidogrelClopidogrel Bisulfate56$642
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen29$119
Hydromorphone Hcl11$94
Oxycodone Hcl11$80

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonXarelto$132$11,92214 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 28 vascular surgery providers in Idaho.

Other vascular surgery in Twin Falls

See the full list for Idaho

Where these figures come from

Is this you, or does something look wrong? →